Scholars Central

OtherPublished 27 Jul 2016

Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus

Authors: Giuseppe Derosa, Sibilla AT Salvadeo, Arrigo FG Cicero

Clinical Practice

Volume 3 · Issue 5 · Pages 559

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Rosiglitazone and glimepiride are effective antihyperglycemic agents approved for the treatment of Type 2 diabetes mellitus. Primarily, rosiglitazone increases insulin sensitivity, while glimepiride stimulates insulin release from β-cells in the pancreas. Combination therapy is often required to achieve effective glycemic control. A fixed-dose formulation of rosiglitazone plus glimepiride has recently been approved in the EU and US for treatment of Type 2 diabetes. Much data demonstrate the advantages of the combination therapy compared with rosiglitazone or glimepiride as monotherapy. Rosiglitazone plus glimepiride is generally well tolerated in all studies and presents a tolerability profile similar to that of monotherapy with rosiglitazone and sulphonylurea. The aim of this review is to present this new fixed-dose combination, which represents a promising new strategy to obtain recommended glycemic control.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Giuseppe Derosa”
  • BylineArticles whose byline prints “Sibilla AT Salvadeo”
  • BylineArticles whose byline prints “Arrigo FG Cicero”